» Articles » PMID: 23050510

The FDA's Assessment of Two Drugs for Chronic Weight Management

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2012 Oct 12
PMID 23050510
Citations 71
Authors
Affiliations
Soon will be listed here.
Citing Articles

Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS.

Harrington J Heart Fail Rev. 2024; 29(5):939-944.

PMID: 38965119 DOI: 10.1007/s10741-024-10410-0.


Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review.

Conde K, Fang S, Xu Y Cell Biosci. 2023; 13(1):143.

PMID: 37550777 PMC: 10408233. DOI: 10.1186/s13578-023-01091-7.


Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management.

Shaik Mohamed Sayed U, Moshawih S, Goh H, Kifli N, Gupta G, Singh S Front Pharmacol. 2023; 14:1182937.

PMID: 37408757 PMC: 10318930. DOI: 10.3389/fphar.2023.1182937.


Cyclophilin B, a molecule chaperone, promotes adipogenesis in 3T3‑L1 preadipocytes via AKT/mTOR pathway.

Yoon J, Kim S, Ha J, Kang I, Choe W Int J Mol Med. 2022; 51(1).

PMID: 36484370 PMC: 9747202. DOI: 10.3892/ijmm.2022.5209.


Delineating a serotonin 1B receptor circuit for appetite suppression in mice.

Li L, Wyler S, Leon-Mercado L, Xu B, Oh Y, Swati J Exp Med. 2022; 219(8).

PMID: 35796804 PMC: 9270184. DOI: 10.1084/jem.20212307.